Seminars in Hematology
Volume 44, Supplement 5 , Pages S12-S23, October 2007

Current Options for the Treatment of Idiopathic Thrombocytopenic Purpura

  • Donald M. Arnold
    • ,
  • John G. Kelton

      Affiliations

    • Corresponding Author InformationAddress correspondence to John G. Kelton, MD, McMaster University, 1200 Main St W, Room 2E1, Hamilton, Ontario, Canada L8N 3Z5.

Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Financial support for the development of this article was provided by an independent grant from GlaxoSmithKline. Funding: D.M.A. is a New Investigator for the Canadian Institutes for Health Research. J.G.K. is a Canada Research Chair.STATEMENT OF CONFLICT OF INTEREST: Dr Kelton has received consulting fees from GlaxoSmithKline. Dr Arnold has received grant/research support from the Canadian Blood Services, and has received grant monies from Hoffman-LaRoche; he will discuss the unlabeled/unapproved use of rituximab for idiopathic thrombocytopenic purpura.

PII: S0037-1963(07)00160-6

doi:10.1053/j.seminhematol.2007.11.003

Seminars in Hematology
Volume 44, Supplement 5 , Pages S12-S23, October 2007

Article Tools

* Image Usage & Resolution